Enhancing oral contraceptive success: The potential of new formulations

American Journal of Obstetrics and Gynecology

Volumn 190, Issue 4 SUPPL., 2004, Pages

  Kaunitz, Andrew M ^a  

^a UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

Author keywords

Cycle control; Desogestrel; Drospirenone; Norgestimate; Safety; Tolerability

Indexed keywords

DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORETHISTERONE; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; ETHINYLESTRADIOL PLUS TRIDESOGESTREL; ETHINYLESTRADIOL PLUS TRINORGESTIMATE; GESTAGEN; GESTODENE; LEVONORGESTREL; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACNE; AMENORRHEA; BREAKTHROUGH BLEEDING; BREAST TENDERNESS; CLINICAL TRIAL; DEPRESSION; DRUG ACTIVITY; DRUG CONTRAINDICATION; DRUG FORMULATION; DRUG LABELING; DRUG MECHANISM; DRUG SAFETY; DYSMENORRHEA; FEMALE; HEADACHE; HUMAN; HYPERKALEMIA; MASTALGIA; MENTAL INSTABILITY; MIGRAINE; NAUSEA; ORAL CONTRACEPTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SPOTTING; STOMACH DISTENSION; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM; WEIGHT GAIN; WITHDRAWAL BLEEDING;

EID: 2342434170     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2004.01.062     Document Type: Article

References (46)

1. Kaunitz AM. Combination oral contraceptives. Contemp Clin Gynecol Obstet 2001;1:149-66.
2. Kaunitz AM. Noncontraceptive health benefits of oral contraceptives. Rev Endocr Metab Disord 2002;3:277-83.
3. Mishell DR Jr. Oral contraception: past, present, and future perspectives. Int J Fertil 1991;36:7-18.
4. Phillips A, Hahn DW, Klimek S, McGuire JL. A comparison of the potencies and activities of progestogens used in contraceptives. Contraception 1987;36:181-92.
5. Phillips A, Demarest K, Hahn DW, Wong F, McGuire JL. Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins. Contraception 1990;41:399-410.
6. Chapdelaine A, Desmarais J-L, Derman RJ. Clinical evidence of the minimal androgenic activity of norgestimate. Int J Fertil 1989;34:347-52.
7. Becker H. Supporting European data on a new oral contraceptive containing norgestimate. Acta Obstet Gynecol Scand Suppl 1990;152:33-9.
8. Burkman RT, Kafrissen ME, Olson W, Osterman J. Lipid and carbohydrate effects of a new triphasic oral contraceptive containing norgestimate. Acta Obstet Gynecol Scand 1992;71(Suppl 156):5-8.
9. Corson SL. Efficacy and safety of a monophasic and a triphasic oral contraceptive containing norgestimate. Am J Obstet Gynecol 1994;170:1556-61.
10. Sulak P, Lippman J, Siu C, Massaro J, Godwin A. Clinical comparison of triphasic norgestimate/35 μg ethinyl estradiol and monophasic norethindrone acetate/20 μg ethinyl estradiol: cycle control, lipid effects, and user satisfaction. Contraception 1999;59:161-6.
11. Lucky AW, Henderson TA, Olson WH, Robisch DM, Lebwohl M, Swinyer LJ. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol 1997;37:746-54.
12. Redmond GP, Olson WH, Lippman JS, Kafrissen ME, Jones TM, Jorizzo JL. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol 1997;89:615-22.
13. Kaplan B. Desogestrel, norgestimate, and gestodene: the newer progestins. Ann Pharmacother 1995;27:736-42.
14. Runnebaum B, Grunwald K, Rabe T. The efficacy and tolerability of norgestimate/ethinyl estradiol (250 μg of norgestimate/35 μg of ethinyl estradiol): results of an open, multicenter study of 59,701 women. Am J Obstet Gynecol 1992;166:1963-8.
15. Redmond G, Godwin AJ, Olson W, Lippman JS. Use of placebo controls in an oral contraceptive trial: methodological issues and adverse event incidence. Contraception 1999;60:81-5.
16. Collins D. Selectivity information on desogestrel. Am J Obstet Gynecol 1993;168:1010-6.
17. Burkman RT. Lipid metabolism effects with desogestrel-containing oral contraceptives. Am J Obstet Gynecol 1993;168:1033-40.
18. Crook D. Multicentre study of endocrine function and plasma lipids and lipoproteins in women using oral contraceptives containing desogestrel progestin. UK Desogen Study Group. Contraception 1997;55:219-24.
19. Shoupe D. Effects of desogestrel on carbohydrate metabolism. Am J Obstet Gynecol 1993;168:1041-7.
20. Schiff CP, Thomas CM, Demacker PN, Doesburg WM, Rolland R. The influence of the triphasic pill and desogestrel-containing combination pill on some physical, biochemical and hormonal parameters: a preliminary report. In: Roland R, editor. Advances in fertility control and the treatment of sterility. Lancaster: MTP Press; 1984. p. 61-70.
21. Jandrain BJ, Humblet DM, Jaminet CG, Scheen AJ, Gaspard UJ, Lefebvre PJ. Effects of ethinyl estradiol combined with desogestrel and cyproterone acetate on glucose tolerance and insulin response to an oral glucose load: a one-year randomized, prospective comparative trial. Am J Obstet Gynecol 1990;163:378-81.
22. Luyckx AS, Gaspard AUJ, Romus MA, Grigorescu F, De Meyts P, Lefebvre PJ. Carbohydrate metabolism in women who used oral contraceptives containing levonorgestrel or desogestrel: a 6-month prospective study. Fertil Steril 1986;45:635-42.
23. van der Vange N, Kloosterboer HJ, Haspels AA. Effect of seven low-dose combined oral contraceptive preparations on carbohydrate metabolism. Am J Obstet Gynecol 1987;156:918-22.
24. Corson SL. Contraceptive efficacy of a monophasic oral contraceptive containing desogestrel. Am J Obstet Gynecol 1993;168:1017-20.
25. Akerlund M, Rode A, Westergaard J. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol. BJOG 1993;100:832-8.
26. Notelovitz M. Contraceptive efficacy and safety of a monophasic oral contraceptive containing 150 micrograms desogestrel and 30 micrograms ethinyl estradiol: United States clinical experience using a "Sunday start" approach. Fertil Steril 1995;64:261-6.
27. Walling M. A multicenter efficacy and safety study of an oral contraceptive containing 150 micrograms desogestrel and 30 micrograms ethinyl estradiol. Contraception 1992;46:313-26.
28. Carr BR. Cycle control with desogestrel-containing oral contraceptives - comparison of a monophasic and triphasic regimen. Int J Fertil Menopausal Stud 1993;38:274-9.
29. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995;346:1582-8.
30. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995;346:1589-93.
31. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995;346:1593-6.
32. Jick H, Kaye JA, Vasilakis-Scaramozza C, Jick S. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ 2000;321:1190-5.
33. Muhn P, Fuhrmann U, Fritzemeier K-H, Krattenmacher R, Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann NY Acad Sci 1995;761:311-35.
34. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000;62:29-38.
35. Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the rennin-aldosterone system, body weight, blood pressure, glucose tolerance and lipid metabolism. J Clin Endocrinol 1995;80:1816-21.
36. Oelkers W, Helmerhorst FM, Wuttke W, Heithecker R. Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers. Gynecol Endocrinol 2000;14:204-13.
37. Parsey KS, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 2000;61:105-11.
38. Sheldon T. Dutch GPs warned against new contraceptive pill. BMJ 2002;324:869.
39. Yasmin: an oral contraceptive with a new progestin. Med Lett 2002;44:55-7.
40. Foidart J-M, Suttke W, Bouw GM, Gerlinger C, Heithecker R. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 2000;5:124-34.
41. DelConte A, Loffer F, Grubb GS. Cycle control with oral contraceptives containing 20 μg of ethinyl estradiol. A multicenter, randomized comparison of levonorgestrel/ethinyl estradiol (100 μg/20 μg) and norethindrone/ethinyl estradiol (1000 μg/20 μg). Contraception 1999;59:187-93.
42. Hampton RM, Short M, Bieber E, Bouchard C, Ayotte N, Shangold G, et al. Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20. Contraception 2001;63:289-95.
43. Kaunitz AM. Efficacy, cycle control, and safety of two triphasic oral contraceptives: Cyclessa (desogestrel/ethinyl estradiol) and Ortho-Novum 7/7/7 (norethindrone/ethinyl estradiol): a randomized clinical trial. Contraception 2000;61:25-302.
44. Cyclessa (desogestrel/ethinyl estradiol) Tablets prescribing information. Physicians' Desk Reference. Montvale, NJ: Medical Economics Company, Inc; 2002. p. 2450-8.
45. Yasmin 28 Tablets (drospirenone and ethinyl estradol) prescribing information. Physicians' Desk Reference. Montvale, NJ: Medical Economics Company, Inc; 2002. p. 980-8.
46. Huber J, Foidart JM, Wuttke W, Merki-Feld GS, The HS, Gerlinger C, et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 2000;5:25-35.